...
首页> 外文期刊>Current Pharmaceutical Biotechnology >Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF): Surgical Adjuvants, Preparations for In Situ Regenerative Medicine and Tools for Tissue Engineering
【24h】

Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF): Surgical Adjuvants, Preparations for In Situ Regenerative Medicine and Tools for Tissue Engineering

机译:富血小板血浆(PRP)和富血小板纤维蛋白(PRF):外科手术佐剂,原位再生医学制剂和组织工程工具

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The recent developement of platelet concentrate for surgical use is an evolution of the fibrin glue technologies used since many years. The initial concept of these autologous preparations was to concentrate platelets and their growth factors in a plasma solution, and to activate it into a fibrin gel on a surgical site, in order to improve local healing. These platelet suspensions were often called Platelet-Rich Plasma (PRP) like the platelet concentrate used in transfusion medicine, but many different technologies have in fact been developed; some of them are even no more platelet suspensions, but solid fibrin-based biomaterials called Platelet-Rich Fibrin (PRF). These various technologies were tested in many different clinical fields, particularly oral and maxillofacial surgery, Ear-Nose-Throat surgery, plastic surgery, orthopaedic surgery, sports medicine, gynecologic and cardiovascular surgery and ophthalmology. This field of research unfortunately suffers from the lack of a proper accurate terminology and the associated misunderstandings, and the literature on the topic is quite contradictory. Indeed, the effects of these preparations cannot be limited to their growth factor content: these products associate many actors of healing in synergy, such as leukocytes, fibrin matrix, and circulating progenitor cells, and are in fact as complex as blood itself. If platelet concentrates were first used as surgical adjuvants for the stimulation of healing (as fibrin glues enriched with growth factors), many applications for in situ regenerative medicine and tissue engineering were developed and offer a great potential. However, the future of this field is first dependent on his coherence and scientific clarity. The objectives of this article is to introduce the main definitions, problematics and perspectives that are described in this special issue of Current Pharmaceutical Biotechnology about platelet concentrates.
机译:外科用血小板浓缩物的最新发展是多年来使用的纤维蛋白胶技术的发展。这些自体制剂的最初概念是将血小板及其生长因子浓缩在血浆溶液中,并在手术部位将其激活为纤维蛋白凝胶,以改善局部愈合。这些血小板悬浮液通常被称为富血小板血浆(PRP),就像输血医学中使用的血小板浓缩液一样,但实际上已经开发了许多不同的技术。其中一些甚至不再是血小板悬浮液,而是基于固体纤维蛋白的生物材料,称为富含血小板的纤维蛋白(PRF)。这些不同的技术已在许多不同的临床领域中进行了测试,特别是口腔和颌面外科,耳鼻喉外科,整形外科,骨科外科,运动医学,妇科和心血管外科以及眼科。不幸的是,该研究领域缺乏适当的准确术语和相关的误解,并且有关该主题的文献非常矛盾。的确,这些制剂的作用不能局限于它们的生长因子含量:这些产品协同协同作用的许多治疗因子,例如白细胞,血纤蛋白基质和循环祖细胞,实际上与血液本身一样复杂。如果首先将血小板浓缩液用作刺激愈合的外科手术佐剂(因为纤维蛋白胶富含生长因子),那么原位再生医学和组织工程的许多应用便得到了开发,并具有巨大的潜力。但是,该领域的未来首先取决于他的连贯性和科学清晰度。本文的目的是介绍《当前医药生物技术》这一期特刊中有关浓缩血小板的主要定义,问题和观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号